Effect of human erythropoietin (hEPO) treatment on anemia in ICR-derived glomerulonephritis (ICGN) mice.
ICR-derived glomerulonephritis (ICGN) mice are a novel inbred strain with hereditary nephrotic syndrome and are thus considered a good animal model of human idiopathic nephrotic syndrome. In the present study, we investigated the effect to erythrocyte production by human erythropoietin (hEPO) treatment in ICGN mice during the early nephrotic stage. Erythrocyte count, hemoglobin concentration and hematocrit value in hEPO-treated (5 U/body/day, for 5 days) ICGN mice were recovered to the levels found in normal ICR mice. In addition, there was no correlation between plasma creatinine level, a marker of renal function, and erythrocyte count after hEPO treatment. Therefore, anemia in ICGN mice may be caused by decreased production of EPO in the kidney following progressive parenchymal damage.
Miyamoto
Yohei
Y
Toxicology Laboratory, Pharmaceutical Research Laboratories, Toray Industries, Inc., Kanagawa, Japan.
Kuramitsu-Miyamoto
Keiko
K
Iwanaga
Ema
E
Uchio-Yamada
Kozue
K
Yamaguchi-Yamada
Misuzu
M
Ogura
Atsuo
A
Manabe
Noboru
N
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000818:Animals; D001774:Blood Chemical Analysis; D004195:Disease Models, Animal; D004920:Erythropoiesis; D004921:Erythropoietin / Q000096:biosynthesis / Q000172:deficiency / Q000627:therapeutic use*; D005260:Female; D006403:Hematologic Tests; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009404:Nephrotic Syndrome / Q000150:complications* / Q000378:metabolism; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin